[HTML][HTML] WITHDRAWN: Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran …
H Inoue, S Uchiyama, H Atarashi, K Okumura… - Journal of …, 2019 - Elsevier
The Publisher regrets that this article is an accidental duplication of an article that has
already been published in Journal of Cardiology, 73/6 (2018) 507–514, https://doi …
already been published in Journal of Cardiology, 73/6 (2018) 507–514, https://doi …
[PDF][PDF] REAL-WORLD EFFECTIVENESS AND SAFETY OF DIRECT ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH NONVALVULAR ATRIAL …
S Suwatcharangkoon - rama.mahidol.ac.th
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia with increasing
prevalence over the past decades. 1, 2 Patients with AF increased risk for hospitalization …
prevalence over the past decades. 1, 2 Patients with AF increased risk for hospitalization …
[引用][C] Η σχέση των νεότερων αντιπηκτικών φαρμάκων με τις αιμορραγίες πεπτικού στους ηλικιωμένους
Χ Βερετάνος
[PDF][PDF] FATORES DETERMINANTES NA RECANALIZAÇÃO DA TROMBOSE VENOSA PROFUNDA. ESTUDO RETROSPECTIVO.
RF Pecorari - 2019 - repositorio.unicamp.br
RESUMO O objetivo desse estudo consistiu em correlacionar fatores determinantes na
recanalização de veias afetadas pela trombose venosa profunda (TVP), em pacientes …
recanalização de veias afetadas pela trombose venosa profunda (TVP), em pacientes …
Apport des méthodes méta-épidémiologiques pour la quantification du biais d'évaluation dans les études observationnelles: exemple avec les anticoagulants oraux …
M Safieddine - 2020 - theses.hal.science
Les essais contrôlés randomisés (ECR) sont considérés comme la méthode de référence
pour évaluer l'efficacité et la sécurité d'un traitement et sont donc nécessaires pour obtenir …
pour évaluer l'efficacité et la sécurité d'un traitement et sont donc nécessaires pour obtenir …
臨床現場における薬剤師の役割(13) 付属病院の患者データに基づいた経口抗凝固薬の抗凝固作用の推定
宇波奈央子， 伊勢雄也 - 日本医科大学医学会雑誌, 2024 - jstage.jst.go.jp
抄録 The incidence of cerebral infarction in patients with non-valvular atrial fibrillation is 5%
per year on average, and since there are currently estimated to be more than 800,000 …
per year on average, and since there are currently estimated to be more than 800,000 …
[PDF][PDF] 本編は次ページより掲載しております.
用語集 - jsth.org
抗リン脂質抗体症候群 (APS) は抗リン脂質抗体 (aPL) と呼ばれる自己抗体が産生され,
動脈血栓症, 静脈血栓症, 習慣性流産などを引き起こす自己免疫疾患である. APS 国際分類基準の …
動脈血栓症, 静脈血栓症, 習慣性流産などを引き起こす自己免疫疾患である. APS 国際分類基準の …
静脈血栓塞栓症の臨床研究とデータベース研究における統計学の役割
小椋透 - 日本血栓止血学会誌, 2018 - jstage.jst.go.jp
静脈血栓塞栓症の発症割合は状況や部位によっては数% である. 日本で静脈血栓塞栓症を評価
項目とした並行群間比較試験は実施されているが, 両群ともに静脈血栓塞栓症の発症が少なく …
項目とした並行群間比較試験は実施されているが, 両群ともに静脈血栓塞栓症の発症が少なく …
[引用][C] Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry
MD Zhimin Dong, MD Xiaoxia Hou, MD Xin Du… - 2022 - europepmc.org
Abstract Background: Direct oral anticoagulants (DOACs) have increasingly become an
alternative to warfarin in atrial fibrillation (AF) patients. Nonetheless, data on the …
alternative to warfarin in atrial fibrillation (AF) patients. Nonetheless, data on the …